---
title: "Genmab And Abbvie Provide Clarification On Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (Duobody®-Cd3xcd20) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293666607.md"
datetime: "2026-07-23T20:54:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293666607.md)
  - [en](https://longbridge.com/en/news/293666607.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293666607.md)
---

# Genmab And Abbvie Provide Clarification On Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (Duobody®-Cd3xcd20) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)

July 23 (Reuters) - Abbvie Inc (ABBV.N) : \* GENMAB AND ABBVIE PROVIDE CLARIFICATION ON PHASE 3 EPCORE® DLBCL-1 TRIAL EVALUATING EPCORITAMAB (DUOBODY®-CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) \* GENMAB: CLARIFY OVERALL SURVIVAL (OS) WAS SOLE U.S. PRIMARY ENDPOINT IN PHASE 3 EPCORE(®) DLBCL-1 TRIAL AND WAS NOT MET Source text: Further company coverage: (ABBV.N) ((

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial](https://longbridge.com/en/news/293659753.md)
- [AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis](https://longbridge.com/en/news/294086753.md)
- [The Bull Case For AbbVie (ABBV) Could Change Following EU Approval Of Rinvoq For Vitiligo](https://longbridge.com/en/news/294200563.md)
- [First Trust Advisors LP Purchases 1,126,069 Shares of Genmab A/S Sponsored ADR $GMAB](https://longbridge.com/en/news/293838796.md)
- [Genmab Announces Positive Phase 3 Results For Epcoritamab Plus Lenalidomide](https://longbridge.com/en/news/291234509.md)